Meet ChemDiv at the 42nd Annual JPM Healthcare Conference in San Francisco
ChemDiv, a global leader in breakthrough therapies, is excited to be a part of the prestigious 42nd Annual JPM Healthcare Conference, held from January 8th to 11th, 2024, in San Francisco, CA.
"At ChemDiv, our dedication to driving healthcare innovation spans over 32 years,” commented Bill Farley, CEO of ChemDiv. “We eagerly await the conference to connect with fellow innovators, exchange insights, and forge impactful partnerships."
Gathering industry frontrunners, emerging enterprises, technological innovators, and investors, the JPM Healthcare Conference serves as a cornerstone event fostering networking, insightful exchanges, and discussions that shape the future landscape of healthcare.
ChemDiv is dedicated to partnering in discovery and development of breakthrough therapies based on its unique chem-bio platforms: molecular glues, stabilizers and degraders; covalent and non-covalent binders; bifunctional molecules for synergistic effect and synthetic lethality.
Over the past 32 years ChemDiv has successfully completed hundreds of lead, candidate and new drug programs to treat cancer, neurological, infectious, cardiometabolic and immune diseases with pharma, biotech and academic partners around the globe. For more information about ChemDiv, visit www.chemdiv.com.
To schedule a meeting, please contact:
CEO of ChemDiv